Search Tag: MASLD
2025 13 Sep
Metabolic dysfunction-associated steatotic liver disease is highly prevalent, and liver fibrosis remains the key driver of adverse outcomes, making early, accurate staging essential for care pathways and follow-up. Invasive biopsy remains the reference standard yet is unsuitable for routine use, so ultrasound elastography methods are increasingly...Read more
2025 13 Sep
Metabolic dysfunction-associated steatotic liver disease is highly prevalent, and liver fibrosis remains the key driver of adverse outcomes, making early, accurate staging essential for care pathways and follow-up. Invasive biopsy remains the reference standard yet is unsuitable for routine use, so ultrasound elastography methods are increasingly...Read more
2025 20 Jul
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, affects around one quarter of the global population. It is characterised by hepatic steatosis in the presence of cardiometabolic risk factors and in the absence of other liver diseases or excessive alcohol consumption. A subset...Read more
2025 20 Jul
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, affects around one quarter of the global population. It is characterised by hepatic steatosis in the presence of cardiometabolic risk factors and in the absence of other liver diseases or excessive alcohol consumption. A subset...Read more
2025 09 Apr
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a prevalent and pressing global health concern, driven largely by rising rates of obesity and metabolic syndrome. Characterised by the accumulation of fat in hepatocytes, MASLD can progress to more severe conditions, including steatohepatitis, fibrosis and even liver...Read more
2025 24 Feb
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become a global health challenge, closely linked to a variety of serious comorbidities, including cardiovascular disease, type 2 diabetes and liver-related complications. As the prevalence of MASLD continues to rise, particularly in populations affected by obesity and insulin resistance,...Read more
2024 23 Jul
An overview of a new tool that converts highly validated ultrasound technology into a software-based application, enabling any clinician to assess and quantify liver stiffness at the point of care and democratise liver assessment—a critical need in light of the increasing prevalence and care burden of MASLD and MASH worldwide. Key...Read more